Back to mobile site

Goldman Sachs Reiterates Conviction Buy Rating on Amgen (AMGN)

October 16, 2024 6:02 AM EDT Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Conviction Buy rating and $369.00 price target on Amgen (NASDAQ: AMGN).The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login